Barna Gábor, Szalóki Gábor, Márk Ágnes, Hunyadi Anna, Kriston Csilla
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Int J Cancer. 2025 Nov 1;157(9):1772-1780. doi: 10.1002/ijc.70028. Epub 2025 Jul 10.
Bypassing the anti-tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA-4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an important role in immune processes. CD86 is widely expressed in hematological tumors, mainly of B-cell origin, and only a few studies are available about its role in the pathogenesis. This study discusses the importance of CD86 expression in hematological malignancies. Does its presence help or hinder the development and survival of tumor cells? The answer to this question will facilitate a more profound comprehension of the biology of hematological malignancies and the development of new therapeutic options.
绕过免疫系统的抗肿瘤功能是肿瘤存活的关键之一。肿瘤，尤其是血液肿瘤，会产生或表达一些因子，这些因子会重新调节T细胞和B细胞以抑制免疫反应。共刺激分子CD28和CTLA-4及其配体CD80和CD86参与免疫突触的形成，并在免疫过程中发挥重要作用。CD86在血液肿瘤中广泛表达，主要起源于B细胞，而关于其在发病机制中的作用的研究较少。本研究探讨了CD86表达在血液系统恶性肿瘤中的重要性。它的存在对肿瘤细胞的发展和存活是有帮助还是有阻碍？这个问题的答案将有助于更深入地理解血液系统恶性肿瘤的生物学特性以及开发新的治疗方案。
